Drug Search Results
More Filters [+]

TOP-1288

Alternative Names: top-1288, top1288, top 1288
Latest Update: 2018-09-20
Latest Update Note: Clinical Trial Update

Product Description

TOP1288, the first in a new class of agents called narrow spectrum protein kinase inhibitors (NSKIs), is being developed as a novel, non-absorbed treatment for ulcerative colitis (UC).

Mechanisms of Action: NSK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Rectal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Topivert Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TOP-1288

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colitis, Ulcerative

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2016-000390-20

P2

Completed

Colitis, Ulcerative

2017-06-28

TOP2

P2

Completed

Colitis, Ulcerative

2017-06-28

TOP1288-TV-03

P1

Completed

Colitis, Ulcerative

2017-06-02

22%

TV-01

P1

Completed

Colitis, Ulcerative

2016-07-01

Recent News Events

Date

Type

Title